Literature DB >> 32717114

CTLA4-Ig prolongs graft survival specifically in young but not old mice.

Timm Heinbokel1,2, Markus Quante1,3, Jasper Iske1,4, Yeqi Nian1, Ryoichi Maenosono1,5, Koichiro Minami1,5, Yang Liu1,6, Haruhito Azuma5, Abdallah Elkhal1, Stefan G Tullius1.   

Abstract

Elderly organ transplant recipients have remained underrepresented in clinical trials, despite representing a rapidly growing population. Here, we assessed age-specific effects of CTLA4-Ig (cytotoxic T-lymphocyte antigen 4-Ig), a fusion protein blocking costimulatory signaling between antigen-presenting cells and T cells through CD28. Cardiac allografts in young mice (2-3 months) treated with CTLA4-Ig survived indefinitely, whereas 80% of old recipients (18 months) had lost their graft after 100 days. CTLA4-Ig was also significantly less effective in older recipients of skin transplants. CTLA4-Ig reduced CD4+ central memory and effector memory T cells and diminished systemic interferon-gamma levels only in young recipients. These differences corresponded to a reduced expression of CD28 on antigen-experienced CD4+ T cells in old mice. In support, adoptive transfer of old CD4+ T cells that were transfected with a lentiviral vector inducing constant expression of CD28 accelerated the rejection of allogeneic skin grafts in young RAG2-/- recipient mice. Regulatory T cells (Tregs), in contrast, demonstrated an increased expression of CD28 with aging and CTLA4-Ig treatment in old recipients resulted in reduced frequencies, compromised proliferation, and diminished suppressive capacity of Tregs. These findings may prove to have unique clinical consequences for immunosuppression in the growing population of elderly transplant recipients.
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  T cell biology; animal models: murine; basic (laboratory) research/science; clinical research/practice; graft survival; heart transplantation/cardiology; immunosuppressant - fusion proteins and monoclonal antibodies; immunosuppressant - fusion proteins and monoclonal antibodies: belatacept; immunosuppression/immune modulation

Mesh:

Substances:

Year:  2020        PMID: 32717114      PMCID: PMC7855762          DOI: 10.1111/ajt.16218

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  49 in total

Review 1.  Rejection and recipient age.

Authors:  Benjamin A Bradley
Journal:  Transpl Immunol       Date:  2002-08       Impact factor: 1.708

2.  Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion.

Authors:  Jean M Fletcher; Milica Vukmanovic-Stejic; Padraic J Dunne; Katie E Birch; Joanne E Cook; Sarah E Jackson; Mike Salmon; Malcolm H Rustin; Arne N Akbar
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

3.  Kidney allocation and the aging immune response.

Authors:  Stefan G Tullius; Edgar Milford
Journal:  N Engl J Med       Date:  2011-03-16       Impact factor: 91.245

4.  Annual Data Report of the US Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR). Preface.

Authors: 
Journal:  Am J Transplant       Date:  2013-01       Impact factor: 8.086

Review 5.  CD28 negative T cells: is their loss our gain?

Authors:  D Mou; J Espinosa; D J Lo; A D Kirk
Journal:  Am J Transplant       Date:  2014-10-16       Impact factor: 8.086

6.  Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus.

Authors:  F Krenzien; M Quante; T Heinbokel; M Seyda; K Minami; H Uehara; H R C Biefer; J M Schuitenmaker; S Gabardi; K Splith; M Schmelzle; A K Petrides; H Azuma; J Pratschke; X C Li; A ElKhal; S G Tullius
Journal:  Am J Transplant       Date:  2016-11-21       Impact factor: 8.086

7.  Prolonged graft survival in older recipient mice is determined by impaired effector T-cell but intact regulatory T-cell responses.

Authors:  Christian Denecke; Damanpreet Singh Bedi; Xupeng Ge; Irene Kyung-Eun Kim; Anke Jurisch; Anne Weiland; Antje Habicht; Xian C Li; Stefan G Tullius
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

8.  CD28 controls differentiation of regulatory T cells from naive CD4 T cells.

Authors:  Fei Guo; Cristina Iclozan; Woong-Kyung Suh; Claudio Anasetti; Xue-Zhong Yu
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

9.  Differential pathways govern CD4+ CD28- T cell proinflammatory and effector responses in patients with coronary artery disease.

Authors:  Behnam Zal; Juan C Kaski; Julius P Akiyu; Della Cole; Gavin Arno; Jan Poloniecki; Alejandro Madrigal; Anthony Dodi; Christina Baboonian
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

Review 10.  CD28(-) T cells: their role in the age-associated decline of immune function.

Authors:  Nan-Ping Weng; Arne N Akbar; Jorg Goronzy
Journal:  Trends Immunol       Date:  2009-06-18       Impact factor: 16.687

View more
  1 in total

1.  Recipient sex and estradiol levels affect transplant outcomes in an age-specific fashion.

Authors:  Ryoichi Maenosono; Yeqi Nian; Jasper Iske; Yang Liu; Koichiro Minami; Tabea Rommel; Friederike Martin; Reza Abdi; Haruhito Azuma; Bernhard A Rosner; Hao Zhou; Edgar Milford; Abdallah Elkhal; Stefan G Tullius
Journal:  Am J Transplant       Date:  2021-06-24       Impact factor: 9.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.